Corbus Pharmaceuticals Holdings, Inc. Cash Flow Statement
CRBP|8 years of annual SEC 10-K data (FY2015-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Corbus Pharmaceuticals Holdings, Inc. used $48M in operating cash flow and negative free cash flow of $48M in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$45.6M | -$111.3M | -$71.5M | -$55.7M | -$32.4M | -$8.9M | -$8.9M | -$2.5M |
| Depreciation & Amortization | $999.8K | $1.1M | $739.4K | $493.9K | $255.7K | $43.9K | $43.9K | $10.4K |
| Operating Cash Flow | -$48.2M | -$99.7M | -$45.7M | -$30.1M | -$27.8M | -$4.6M | -$4.6M | -$2.4M |
| Capital Expenditures | $54.2K | $484.5K | $2.7M | $2.3M | $707.4K | $114.0K | $114.0K | $64.4K |
| Free Cash Flow | -$48.2M | -$100.2M | -$48.5M | -$32.4M | -$28.5M | -$4.7M | -$4.7M | -$2.4M |
| FCF Margin | -5471.0% | -2544.2% | -134.1% | -671.2% | -1168.1% | -730.9% | -730.9% | -374.1% |